TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.